0.876
0.19 (27.19%)
| Penutupan Terdahulu | 0.689 |
| Buka | 0.780 |
| Jumlah Dagangan | 956,184 |
| Purata Dagangan (3B) | 361,309 |
| Modal Pasaran | 37,397,696 |
| Harga / Jualan (P/S) | 1.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -168.23% |
| Margin Operasi (TTM) | -88.72% |
| EPS Cair (TTM) | -1.32 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -9.90% |
| Nisbah Semasa (MRQ) | 0.810 |
| Aliran Tunai Operasi (OCF TTM) | -28.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.41 M |
| Pulangan Atas Aset (ROA TTM) | -38.41% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Elutia, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.67 |
|
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women’s Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.27% |
| % Dimiliki oleh Institusi | 72.64% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Knollwood Investment Advisory, Llc | 30 Sep 2025 | 1,031,567 |
| Birchview Capital, Lp | 30 Sep 2025 | 711,175 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones |
| 09 Jan 2026 | Pengumuman | Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery |
| 06 Nov 2025 | Pengumuman | Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development |
| 23 Oct 2025 | Pengumuman | Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 |
| 14 Oct 2025 | Pengumuman | Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |